Intravenous infusion, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose
Code effective Apr 01, 2026
HCPCS Section
Medical services
M0233 is a valid 2026 HCPCS code meaning Intravenous infusion, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose or (Intra inf, toci, first dose) for short. HCPCS M0233 has been effective since 04/01/2026 and applies to Pneumococcal/flu vaccine.
|
HCPCS Level II Code Section M - Medical services |
|
| HCPCS Code | M0233 |
|---|---|
| Description |
Long description:
Short description: |
| HCPCS Pricing indicator |
54 - Vaccinations
|
| Multiple pricing indicator |
A - Not applicable as HCPCS priced under one methodology
|
| Coverage code | C - Carrier judgment |
| BETOS2 code | O1G - Immunizations/Vaccinations |
| HCPCS Action code | A - Add procedure or modifier code |
| Type of service | V - Pneumococcal/flu vaccine |
| Effective date | Effective Apr 01, 2026 |
| Date added | Added Apr 01, 2026 |
1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).
2 BETOS stands for “Berenson-Eggers Type Of Service”
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/23/2026
CPT® is a registered trademark of the American Medical Association (AMA). All rights reserved.